Abstract 2037P
Background
Prehabilitation is a process that aims to improve a patient's functional capacity before surgery. It may reduce postoperative complications and improve outcomes in cancer patients, particularly those frail. However, the effectiveness of prehabilitation in frail cancer patients undergoing elective surgery is not well understood. This systematic review and meta-analysis aimed to evaluate prehabilitation's effects on postoperative outcomes in frail cancer patients undergoing elective surgery.
Methods
Our search included electronic databases such as PubMed, Embase, and Cochrane and was conducted until January 2022. We had studies that compared a prehabilitation or preoperative optimization program to standard care, postoperative rehabilitation, or a placebo. The primary outcomes of interest were postoperative complications, length of hospital stay, 30-day mortality, and hospital readmission rate. We used R version 4.0.3 and the metafor and meta packages for statistical analysis.
Results
A total of 8 studies met the inclusion criteria for the meta-analysis, with 581 patients in the prehabilitation group and 675 patients in the control group. The results showed that prehabilitation was associated with a significant reduction in postoperative complications (risk ratio (RR) 0.83, 95% confidence interval (CI) 0.69 to 0.98). Prehabilitation was also associated with a significant reduction in length of hospital stay (mean difference -2.32 days, 95% CI -4.34 to -0.29) and a non-significant reduction in 30-day mortality (RR 0.45, 95% CI 0.13 to 1.59). There was no significant difference in hospital readmission rate between the prehabilitation and control groups (RR 1.09, 95% CI 0.38 to 3.15).
Conclusions
Prehabilitation may improve hospital stay and reduce postoperative complications in frail cancer patients undergoing elective surgery. Further research is needed to confirm these findings and determine rehabilitation interventions' optimal duration and intensity. Clinicians need to consider the potential benefits of prehabilitation in caring for frail cancer patients preparing for surgery.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2028TiP - Phase I, non-randomised, open-label, multi-centre dose escalation trial of BI 764532 (DLL3/CD3 IgG-like T cell engager [TcE]) + ezabenlimab (anti-PD-1 antibody) in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs) expressing DLL3
Presenter: Julien Mazieres
Session: Poster session 06
2029TiP - Phase I study of ABBV-706, an anti-SEZ6 antibody-drug conjugate, alone or in combination in adults with advanced solid tumors
Presenter: Sreenivasa Chandana
Session: Poster session 06
2035P - Routine biomarker monitoring does not replace comprehensive clinical assessment in the detection of immunotherapy induced myocarditis
Presenter: Alexandra Johnson
Session: Poster session 06
2036P - Prevalence and risk evaluation of cardiovascular disease among newly diagnosed prostate cancer population in China
Presenter: Weiyu Zhang
Session: Poster session 06
2039P - Primary endpoints of confirmatory randomized controlled trials for older patients with cancer: A scoping review
Presenter: Tomonori Mizutani
Session: Poster session 06
2041P - The prevalence of hematologic adverse events (HAEs) and myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) in patients (pts) with advanced high grade ovarian carcinoma (aHGOC) receiving PARP inhibitor (PARPi), with or without a germline BRCA pathogenic variant
Presenter: Carmine Valenza
Session: Poster session 06
2042P - Improving breast cancer outcomes for indigenous women
Presenter: Vita Christie
Session: Poster session 06
2043P - Can Charlson Comorbidity Index (CCI) and Clinical Frailty Scale (CFS) assessments predict survival in octogenarians with colorectal cancer?
Presenter: Neda Nikolic
Session: Poster session 06
2044P - Bloodstream infections (BSI) in cancer patients: Epidemiology, antibiotic therapy and risk factors related to mortality
Presenter: Carlos López Jiménez
Session: Poster session 06
2045P - Patient Reported Outcome Measures (PROMs) capturing therapy adherence of cancer patients: A systematic literature review
Presenter: Luise Richter
Session: Poster session 06